SK Bioscience
SK Bioscience is a South Korean pharmaceutical company focused on the development and manufacturing of vaccines. The company is notable for introducing SKYCellflu, the first cell culture influenza vaccine in Korea, and has since expanded its portfolio to include the SKYCellflu Quadrivalent prefilled syringe and a 13-valent Pneumococcal Conjugate Vaccine. In addition to these licensed products, SK Bioscience is actively engaged in the development of several other vaccines, including a recombinant rotavirus vaccine, a new typhoid conjugate vaccine, and an innovative pneumococcal vaccine, often in collaboration with external partners. The company is dedicated to building a robust infrastructure for continuous vaccine development, positioning itself as a key player in the global vaccine landscape.
Top Stages
3 past transactions
Fina Biosolutions
Corporate Round in 2024
Fina Biosolutions is a biotechnology company focused on the discovery, development, and collaboration of novel vaccine conjugates aimed at preventing life-threatening diseases. The company utilizes proprietary chemistry to conjugate, purify, and manufacture complex conjugate vaccines. By employing advanced bioconjugation techniques, Fina Biosolutions provides a range of services, including protein expression, purification, immunoassay design, analytics, training, and consulting. Its mission is to enhance access to life-saving vaccines while also reducing the cost barriers associated with vaccine development and production. Through its innovative approaches, Fina Biosolutions seeks to make significant contributions to public health by improving vaccine availability and efficacy.
Sunflower Therapeutics
Seed Round in 2024
Sunflower Therapeutics is a biotechnology company specializing in next-generation protein manufacturing solutions. Its mission is to enhance global patient access to biological medicines by developing and implementing advanced technologies suitable for worldwide application. The company employs strain engineering, integrated process development, and automated multi-product facilities to create efficient and scalable production methods for proteins. Sunflower Therapeutics prioritizes values such as wellness, integrity, ethics, equity, community, and efficiency in its operations.
Novavax
Post in 2023
Novavax Inc., established in 1987 and headquartered in Gaithersburg, Maryland, is a late-stage biotechnology company dedicated to discovering, developing, and commercializing vaccines to prevent serious infectious diseases worldwide. Its primary focus lies in advancing vaccine candidates through clinical trials, with notable projects including ResVax for RSV in infants via maternal immunization (Phase III), NanoFlu for seasonal influenza in older adults (Phase III), and NVX-CoV2373 for COVID-19 (preclinical). Novavax's proprietary Matrix-M adjuvant enhances immune response and enables lower antigen doses. The company collaborates globally to address urgent health needs, with Europe being its primary revenue source.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.